US · Healthcare · Biotechnology
EPS came in at -0.81 against a street estimate of -0.73 — a miss of 11.0%.
Analysts rate Nurix Therapeutics Inc a buy (16 buy, 2 hold, 0 sell out of 18) with an average price target of $33.93.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.60% |
| Deep Track Capital, LP | 7.45% |
| Vestal Point Capital LP | 6.26% |
| FMR Inc | 5.34% |
| State Street Corp | 4.95% |
| Morgan Stanley - Brokerage Accounts | 4.75% |
| Baker Bros Advisors LP | 4.49% |
| Vanguard Capital Management, LLC | 4.27% |
| Document | Date |
|---|---|
| Quarterly report · Q2 FY2026 NURIX THERAPEUTICS, INC. – FORM 10-Q SUMMARY For Quarter Ended May 31, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $443.5 | 2026-07-09 |
| Results announced · Q3 FY2026 NURIX THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $443.5 million in cash, cash equivalents and marketable secur | 2026-07-09 |
| Reg FD disclosure · Q3 FY2026 NURIX THERAPEUTICS, INC. - FORM 8-K SUMMARY Date of Report: June 11, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Drug Program: Bexobrutideg (NX-5948), | 2026-06-11 |
| Material agreement · Q3 FY2026 NURIX THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Upfront payment from Roche: $700.0 million cash to Nurix • Total potential payments: | 2026-06-08 |
| Shareholder vote results · Q2 FY2026 NURIX THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 15, 2026 with 83,747,013 shares present or by proxy • Quorum | 2026-05-15 |
| Quarterly report · Q1 FY2026 NURIX THERAPEUTICS, INC. - Q1 2026 (ENDED FEBRUARY 28, 2026) SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Cash & Marketable Securities: $71. | 2026-04-08 |
| Proxy statement · Q2 FY2026 NURIX THERAPEUTICS, INC. – PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Arthur T. Sands, M.D., Ph.D. (President & Chief Executive Officer) – comp | 2026-03-27 |
| Annual report FY2025 NURIX THERAPEUTICS, INC. – FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization (as of May 30, 2025): $807.5 million based on non-affiliate ho | 2026-01-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nurix Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.